lisa-giles

GenMark Diagnostics performs board shuffle

pharmafile | February 26, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing genmark diagnostics, lisa giles, michael kagnoff 

US diagnostic systems provider GenMark Diagnostics has named two new board members whilst announcing a resignation. 

Lisa Giles (pictured) who is the president and chief executive of Giles & Associates Consultancy joins the firm, along with Michael Kagnoff who is a partner at DLA Piper. Steve Worland has resigned from the board.

Giles has served at her current consultancy since 2000, and as chief executive of Optivara since 2013. From 1996-2000 she was VP of strategy development at GD Searle & Company.

Advertisement

Giles previously served as a member of the board of directors of Durata Therapeutics from August 2012 until its acquisition by Actavis in November last year.

Kagnoff has served as a partner at DLA Piper (US) since April 2008. Prior to this he was a stockholder at Heller Ehrman. Kagnoff has been advising boards of directors of both public and private companies for over 20 years, with a focus on life sciences and technology. 

“We are delighted to have Lisa and Mike join our board. Their skill sets are complementary to the deep operational and technical expertise of our other directors and will benefit GenMark and our stockholders immensely,” says Jim Fox, GenMark’s chairman.

“I would also like to thank Steve Worland for his service and respect his recent decision to resign from the board to focus on his role as chief executive and president of eFFECTOR Therapeutics.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content